Most people researching NAD+ precursors encounter the same three options: NMN, NR, and NADH. NMNH — nicotinamide mononucleotide hydride, the reduced form of NMN — is a newer entrant that has not yet reached mainstream awareness but has attracted serious attention from researchers for one specific reason: in the studies conducted so far, it raises NAD+ levels more effectively than NMN at comparable doses.
That claim deserves scrutiny. The research base for NMNH is thin, and most of it comes from a single research group working primarily in animal models. This article explains what NMNH is, what the current evidence shows, how it compares to established precursors, and how to think about it if you are considering adding it to your stack — or waiting for more data before doing so.
What Is NMNH?
NMNH is the reduced form of NMN. The distinction between “oxidized” and “reduced” refers to the compound’s electron state: NMN is the oxidized form, NMNH is the reduced form carrying an additional hydrogen atom (and therefore an additional electron pair). This is the same relationship that exists between NAD+ and NADH — the oxidized and reduced forms of nicotinamide adenine dinucleotide.
To understand where NMNH fits in the broader pathway, it helps to have a picture of how the body converts precursors into NAD+. That full pathway — from NMN through to NAD+ and NADH — is covered in the article on the NAD+ pathway explained. The short version relevant here: NMNH, once absorbed, is converted to NADH, which can then be oxidized to NAD+. This gives NMNH a somewhat different route to NAD+ elevation compared to NMN, which enters the salvage pathway more directly.
NMNH is not a synthetic invention with no natural precedent. Small amounts exist endogenously as part of normal cellular metabolism. What is new is its development as a supplemental compound and the early research suggesting its potency exceeds that of NMN.
The Research Behind NMNH
The scientific case for NMNH rests primarily on a series of studies from a research group led by Dr. Charles Brenner — one of the leading figures in NAD+ biology and the scientist who first characterized NR as an NAD+ precursor. The key paper establishing NMNH as a supplement candidate was published by Zapata-Pérez et al. (2021) in iScience.
The iScience Study: Key Findings
The Zapata-Pérez study compared NMNH to NMN in cell cultures and in mice, measuring NAD+ and NADH levels in multiple tissues. The results were striking by preclinical standards:
In cell culture, NMNH raised NAD+ levels more rapidly and to a higher peak than equivalent doses of NMN. The effect was observed within two hours and was substantially larger — in some cell lines, NMNH produced NAD+ increases two to eight times greater than NMN at the same concentration.
In mice, a single oral dose of NMNH produced significantly higher liver NAD+ levels than an equivalent NMN dose. The increase was rapid — measurable within an hour — and the effect extended to NADH as well, meaning the redox ratio (the balance between NAD+ and NADH) shifted in ways that differ from NMN supplementation.
The researchers also found that NMNH was well-tolerated in mice across the doses tested, with no signs of toxicity at supplementally relevant amounts.
What the Redox Shift Means
This is where NMNH gets more nuanced, and where some researchers have urged caution. NMN supplementation primarily raises NAD+, the oxidized form. NMNH raises both NAD+ and NADH. NADH is the electron carrier — the “charged” form produced when NAD+ accepts electrons during energy metabolism.
Whether raising NADH alongside NAD+ is beneficial, neutral, or potentially counterproductive in certain contexts is not fully worked out. In the short term, a higher NADH level supports mitochondrial energy production. Over longer supplementation, the implications for the NAD+/NADH ratio — which functions as a cellular redox sensor — are not yet characterized in humans. This is a genuine open question, not a reason to assume NMNH is harmful, but it is a reason to distinguish NMNH from NMN rather than treating them as interchangeable.
How NMNH Compares to NMN and NR
Understanding where NMNH sits relative to established precursors requires looking at three dimensions: mechanism, potency, and evidence base.
Mechanism
NMN enters NAD+ biosynthesis via the salvage pathway, where it is converted to NAD+ by the enzyme NMNAT. NR follows a slightly different salvage route, first being phosphorylated to NMN before proceeding to NAD+. NMNH takes yet another path: it is converted to NADH, which is then available for oxidation to NAD+ through the electron transport chain and other redox reactions.
This mechanistic distinction is relevant because it means NMNH’s NAD+-raising effect is partly indirect — it depends on cellular redox activity to convert NADH back to NAD+. In tissues with high metabolic activity (muscle, liver, heart), this conversion happens readily. In lower-activity tissues, the conversion may be slower or less complete.
For a comprehensive look at how NMN and NR compare through their more established pathways, see the article on NMN vs. NR.
Potency
On a per-milligram basis, NMNH appears more potent than NMN in the available preclinical data. The Zapata-Pérez study suggests NMNH may achieve comparable or greater NAD+ elevation at lower doses. Whether this translates proportionally in humans — given differences in gut metabolism, absorption, and tissue distribution — is not established.
Evidence Base
This is the most significant difference. NMN has been through multiple human clinical trials, including randomized controlled trials showing NAD+ elevation, improvements in muscle insulin sensitivity, and other metabolic effects. NR has an even larger human trial base, with well-characterized safety and pharmacokinetics across dozens of studies. NMNH has no published human clinical trials as of mid-2025. Its evidence base is entirely preclinical.
That gap matters. Compelling preclinical data does not reliably predict human outcomes — a lesson the broader supplement field has learned repeatedly. NMNH may prove to be as effective in humans as the mouse data suggests, or it may not. No one currently knows.
Availability and Formulation
NMNH is available from a small number of supplement manufacturers, though the market is significantly thinner than for NMN or NR. Because it is a reduced compound, NMNH is more chemically reactive than NMN and more susceptible to oxidation — meaning formulation and storage matter more. Quality NMNH products should be manufactured under conditions that minimize oxidation and packaged to limit exposure to air and moisture.
Stability is a legitimate concern when evaluating NMNH products. A supplement that degrades during shipping or sits on a shelf for months before use may deliver less active compound than the label suggests. This is an argument for buying from manufacturers who provide third-party testing and who demonstrate attention to stability in their formulation process.
Doses in available products typically range from 100 mg to 300 mg. Given the higher preclinical potency, lower doses than typical NMN protocols are plausible, but without human dose-finding studies, the right dose range in humans is genuinely unknown.
Who Might Consider NMNH
NMNH is not the right choice for someone new to NAD+ supplementation. If you have not tried NMN or NR, starting with either of those established precursors is the more evidence-supported approach. Both have decades of human safety data and multiple clinical trials backing their use. For guidance on those options, the complete guides to NMN and NR cover what you need.
NMNH is worth considering for people who:
- Have used NMN or NR for a significant period and want to explore whether a different precursor produces a different or stronger effect
- Are actively following the NAD+ precursor research landscape and are comfortable making decisions with incomplete human data
- Are working with a longevity-focused clinician who is monitoring NAD+ levels and can track the effect of switching or adding a precursor
It is not appropriate to frame NMNH as a straightforward upgrade over NMN at this stage of the research. It is a compelling candidate that warrants watching — and may well prove to be the more potent option as human data accumulates — but it is not yet established as such.
Safety: What We Know and Don’t Know
Preclinical toxicity data for NMNH is reassuring at doses relevant to supplementation. The Zapata-Pérez study found no adverse effects in mice, and NMNH’s structural relationship to NMN — a compound with an excellent human safety record — is encouraging.
The honest assessment is that human safety data is simply absent. Short-term use at modest doses by healthy adults carries what appears to be low theoretical risk, given the preclinical profile and the compound’s endogenous nature. Long-term effects, drug interactions, and safety in populations with specific health conditions are entirely uncharacterized in clinical research.
This is not a disqualifying concern for an informed adult making a deliberate choice, but it is worth stating plainly: NMNH is a less-tested compound, and anyone using it is doing so ahead of the human clinical evidence that would normally support supplementation recommendations.
The Bottom Line on NMNH
NMNH is the most biochemically interesting new NAD+ precursor to emerge in the past several years. The preclinical data is genuinely impressive, and the compound’s mechanism — while distinct from NMN — is coherent and well-characterized at the cellular level. Dr. Brenner’s group has a strong track record in NAD+ research, which adds credibility to the early findings.
The limitation is the complete absence of human clinical data. For a supplement that you would be taking daily over months or years, that gap matters. NMN and NR have earned their positions in longevity stacks through accumulated human evidence. NMNH has not yet done that work, and it may be two to four years before it has.
Watch this space. If and when the first human pharmacokinetic and efficacy trials publish, NMNH’s position in the precursor hierarchy will become clearer. Until then, it belongs in the category of promising compounds that deserve attention — but not yet the front of the stack.
Frequently Asked Questions
Is NMNH better than NMN?
In preclinical studies, NMNH raises NAD+ levels more potently than NMN at comparable doses. Whether this translates to better outcomes in humans is not yet known — there are no published human clinical trials on NMNH. NMN has a well-established human evidence base; NMNH does not. “Better” is premature until human data exists.
Can I take NMNH and NMN together?
There is no known reason they cannot be combined, and their different routes to NAD+ elevation make them theoretically complementary rather than redundant. That said, no research has studied this combination, and combining two precursors with limited safety data for one of them is a choice to make with awareness of that uncertainty.
Why isn’t NMNH more widely known or available?
The primary research establishing NMNH as a supplement candidate was published in 2021, making it genuinely new. Human clinical trials — which typically take several years to design, fund, recruit, conduct, and publish — have not yet appeared. Most supplement manufacturers wait for at least preliminary human safety and efficacy data before building a product around a new compound. The market for NMNH reflects the current state of the science: early and thin.
How does NMNH relate to NADH supplements?
NADH supplements — which have been on the market for years, primarily marketed for energy and cognitive function — deliver the reduced form of NAD+ directly. NMNH is the reduced form of NMN, which converts to NADH before being oxidized to NAD+. They are related but not identical compounds taking somewhat different paths to the same destination. NADH supplements have their own mixed evidence base; NMNH’s preclinical data is more recent and methodologically stronger than much of the older NADH literature.